lnterleukin-15 (IL-15) is cytokine with pleiotropic effects on the ontogeny, homeostasis, and physiology of innate and adaptive immune cells. Our focus over the past decade of this award has been on the association of IL-15 and natural killer (NK) cell biology and pathophysiology. Our progress during this past funding cycle has occurred during a seemingly unprecedented period of advancement in our understanding of NK cell development, biology, and therapeutic application. Our own contributions have revolved around the role of IL-15 in NK cell development and homeostasis at both the cellular and molecular level, including some recent intriguing data that may define the lymph node as a site of human CD56 (bright) NK cell development. We have demonstrated that deregulation of IL-15 leads to a pro-inflammatory cytokine cascade that ultimately results in a high frequency of monoclonal acute lymphoblastic leukemia of the T/NK lineage, establishing IL-15 as a player in the ever-increasing association between inflammation and cancer. Importantly, epigenetic alterations in the genome appear to be central to this process, and we have devised an effective technique to identify novel genes that are clearly targeted and silenced in a non-random fashion in T/NK leukemia. In the next five years of study we will focus on three aims initiated at the time of our last competitive renewal application, each unified by the common theme of IL-15 in innate immunity. We will evaluate: (1) the stages of NK cell development, especially in the context of cytokine responsiveness; (2) the role of two transcription factors that are downstream targets of IL-15 and appear to be involved in NK cell differentiation; (3) the role of IL-15 deregulation in the genesis of experimentally induced T/NK cell acute lymphoblastic leukemia, as well as therapeutic approaches to cure the disorder. Collectively, the work outlined in this proposal should provide important information on how to better manipulate NK cells for anti-leukemia therapy, as well as new insights into the relationship between inflammation and cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA068458-11
Application #
7054146
Study Section
Transplantation, Tolerance, and Tumor Immunology (TTT)
Program Officer
Howcroft, Thomas K
Project Start
1996-07-01
Project End
2010-04-30
Budget Start
2006-05-01
Budget End
2007-04-30
Support Year
11
Fiscal Year
2006
Total Cost
$279,200
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Dai, Hong-Sheng; Caligiuri, Michael A (2018) Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells. Front Immunol 9:183
Wang, Yufeng; Zhang, Yibo; Hughes, Tiffany et al. (2018) Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo-Expanded Autologous NK Cells. Clin Cancer Res 24:4006-4017
Zhang, Xinfu; Zhang, Chengxiang; Yang, Xiaomei et al. (2018) Design, synthesis and evaluation of anti-CD38 antibody drug conjugate based on Daratumumab and maytansinoid. Bioorg Med Chem :
Chen, Luxi; Youssef, Youssef; Robinson, Cameron et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity 49:464-476.e4
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Deng, Youcai; Wang, Fangjie; Hughes, Tiffany et al. (2018) FOXOs in cancer immunity: Knowns and unknowns. Semin Cancer Biol 50:53-64
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
Chan, Wing Keung; Kang, Siwen; Youssef, Youssef et al. (2018) A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma. Cancer Immunol Res 6:776-787
Freud, Aharon G; Mundy-Bosse, Bethany L; Yu, Jianhua et al. (2017) The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity 47:820-833
Chen, L; Mao, H; Zhang, J et al. (2017) Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Leukemia 31:1830-1834

Showing the most recent 10 out of 91 publications